Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Regarding injection site rotation, alternate between different areas like the abdomen, thigh, or upper arm to prevent ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...